Initial non-responders to ranibizumabin the treatment of age-related macular degeneration (AMD)

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1487-1490

  Otsuji, Tsuyoshi ^a   Nagai, Yoshimi ^b   Sho, Kenichiro ^a   Tsumura, Akiko ^a   Koike, Naoko ^a   Tsuda, Mei ^a   Nishimura, Tetsuya ^a   Takahashi, Kanji ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

AMD; Anti VEGF drug; Initial non responders; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84880587327     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S46317     Document Type: Article

References (16)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. for MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al. for ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; for ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
4. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6): 1175-1183.
5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):556-583.
6. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43-58.
7. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis. 2010;16:2598-2604.
8. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci. 2011;52(7):4694-4702.
9. Chen H, Yu KD, Xu GZ. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: A meta-analysis. PLoS One. 2012;7(8): e42464.
10. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularization. Br J Ophthalmol. 2012;96(1):14-20.
11. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21-23.
12. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43(3):830-841.
13. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44(5): 2147-2154.
14. Wachtlin J, Behme T, Heimann H, et al. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2003;241(6):518-521.
15. Ruiz-Moreno JM, Montero JA, Amat P, et al. Macular atrophy after combined intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization. Int J Ophthalmol. 2010;3(2):161-163.
16. Heier JS, Brown DM, Chong V, et al. for VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.